The study, published in PNAS, identified a gene whose expression could be used as a prognostic indicator and could direct treatment in breast cancer patients.
Johns Hopkins Kimmel Cancer Center identified a gene, MACROD2,
A study conducted by scientists at the which they found is amplified in a subset of breast cancer patients. Deletion and overexpression studies with the gene, in vitro and in a mouse model, found that MACROD2 promotes resistance to tamoxifen and encourages estrogen receptor-independent growth in a mouse xenograft model.
When they examined 2 well-known databases of breast cancer patients' genetic information, The Cancer Genome Atlas and the Molecular Taxonomy of Breast Cancer International Consortium study, it was discovered that patients who had MACROD2 overexpressed in primary breast cancers at the original breast cancer site had significantly worse survival rates than those who did not.
This could mean that patients overexpressing this gene in the primary tumor, early in the disease, could receive aggressive treatment.
The study was published online in PNAS: http://bit.ly/1rcTJBY
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen